BCA
SWTX

Berman Capital Advisors’s SpringWorks Therapeutics SWTX Stock Holding History

Berman Capital Advisors’s Portfolio SWTX Stock Details SWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-4
Closed – – 2040
2021
Q1 		$0 Hold
4
– – ﹤0.01% 1903
2020
Q4 		$0 Buy
+4
New +$257 ﹤0.01% 1825

Other funds holding SWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Berman Capital Advisors's SWTX Position: Q2 2021 in Review

Berman Capital Advisors sold out of SpringWorks Therapeutics (SWTX) in Q2 2021, closing a stake of 4 shares.

Berman Capital Advisors first reported a position in SWTX in Q4 2020 and held it in 2 quarters. The position peaked at $0 in Q1 2021. 134 funds tracked by Wall St. Rank hold SWTX as of Q2 2021.

  • Berman Capital Advisors reported no remaining SpringWorks Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Berman Capital Advisors sold 4 SpringWorks Therapeutics shares in Q2 2021.
  • Berman Capital Advisors first reported a position in SpringWorks Therapeutics in Q4 2020 and held it in 2 quarters.
  • Berman Capital Advisors's SpringWorks Therapeutics position peaked at $0 in Q1 2021.
  • 134 funds tracked by Wall St. Rank held SpringWorks Therapeutics as of Q2 2021.

Based on Berman Capital Advisors's 13F filing for Q2 2021, filed 11 Aug 2021.